Stock Movers: Dominion Energy, Regeneron, Hive (Podcast)

Dominion Energy shares rose after NextEra Energy agreed to pay about $67 billion in stock for the company, the largest power acquisition ever. Regeneron fell after its late-stage melanoma study failed to beat Keytruda, while Hive Digital Technologies gained on plans to build a 320-megawatt AI data center in Toronto with more than 100,000 GPUs at full capacity.

Analysis

The utility/M&A angle is less about headline spread capture and more about forced rerating of the regulated asset base. A large strategic buyer with a broader balance-sheet and developer footprint can improve the market’s view of long-duration cash flows, but the second-order winner is likely the adjacent infrastructure stack: transmission, turbine, switchgear, and engineering firms tied to load growth from data centers in Virginia and the Southeast. That said, the bigger strategic signal is consolidation pressure in U.S. regulated power — if this clears, expect competing utilities with underutilized grids near AI hubs to become acquisition candidates over the next 6-12 months.

For biotech, the trial miss does not just hit one pipeline asset; it reinforces a valuation reset on the company’s oncology optionality relative to the established standard-of-care incumbents. The market will likely haircut the probability of success for the remaining head-to-head program, especially because investors now have to assume a lower bar for future combination data. Competitively, this modestly strengthens the incumbent checkpoint franchises and reduces near-term appetite for speculative PD-1 combo names, with read-through risk to smaller biotech partners relying on similar mechanisms.

The AI data-center build is the most underappreciated second-order story. A 320MW site with 100k+ GPUs implies a multi-year power procurement and cooling equipment cycle, which can pull forward demand for grid interconnect, transformers, liquid-cooling systems, and fiber capacity; the first beneficiaries are often not the operator but the vendors selling picks-and-shovels into the buildout. Near term, the stock can stay momentum-driven for days to weeks, but the real catalyst is capital intensity and financing execution over the next 2-4 quarters: if power costs, permitting, or customer pre-commitments slip, the valuation premium can compress quickly.

Key Decisions for Investors

• Long NEE vs. a basket of regulated utilities with weaker AI-load exposure for a 3-6 month horizon; the setup is favorable if the market starts capitalizing data-center demand into utility growth rates, with ~15-20% upside on rerating and limited fundamental downside if the deal closes.
• Short REGN on strength or buy 1-3 month downside puts; the miss raises the odds of a broader oncology multiple de-rate, and the trade works best if the stock fails to reclaim pre-gap levels within 5-10 trading days.
• Pair trade: long grid/power equipment names vs. short high-beta AI infrastructure developers that need heavy project financing, over the next 6-12 months; the former monetize the capex cycle earlier and with less execution risk.
• Speculative long HIVE only as a momentum trade with a tight stop; upside can extend over 2-6 weeks on AI narrative flow, but risk/reward deteriorates quickly if investors question electricity sourcing, customer concentration, or financing for the Toronto build.
• Watch for utility M&A sympathy trades in regionals near load-growth corridors; enter only on pullbacks, because the immediate read-through is positive but follow-through depends on deal terms and regulatory scrutiny.